ReviewNature reviews. Cardiology2019
The role of B cells in atherosclerosis.
Review in Nature reviews. Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cardiovascular events risk in patients with systemic autoimmune diseases: a prognostic systematic review and meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Pooled it
- Meta-Analysis of Single-Cell RNA-Seq Data Reveals the Mechanism of Formation and Heterogeneity of Tertiary Lymphoid Organ in Vascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2023Pooled it
- Anti-Malondialdehyde Low-Density Lipoprotein Antibodies and Valvular Calcification: A Substudy of the SCOT-HEART Trial.Journal of the American Heart Association · 2025Trial
- Rituximab in patients with acute ST-elevation myocardial infarction: an experimental medicine safety study.Cardiovascular research · 2022Trial
- Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody-autoantigen pair in atherosclerosis.Nature cardiovascular research · 2026Article
- Article
- Unveiling the B-cell conundrum in in-stent restenosis.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Mechanism and therapeutic prospects of adipose tissue B lymphocytes in obesity and obesity‑associated metabolic diseases (Review).Molecular medicine reports · 2026Review
- Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy.Cell reports. Medicine · 2026Article
- Polymeric immunoglobulin receptor deficiency attenuates experimental atherosclerosis.Frontiers in immunology · 2026Article
- Metabolic and Inflammatory Mechanisms Driving Atrial Fibrillation.Annual review of pharmacology and toxicology · 2026Review
- Emerging insights into inflammation-driven atherosclerosis: immune cell mechanisms.Frontiers in cardiovascular medicine · 2026Review
- Single-cell sequencing combined with transcriptome analysis unravels LUMFrontiers in immunology · 2026Article
- B cells and B-cell receptor repertoire features in coronary heart disease: immunopathogenic roles, clinical relevance, and therapeutic potential.Frontiers in cardiovascular medicine · 2026Review
- ApoB-specific CD4Frontiers in immunology · 2026Review
- Chemokine-receptor-guided B-cell immunity in cardiovascular disease.Basic research in cardiology · 2025Review
- Novel Murine Model of Atherosclerosis Progression Induced by a Modified Paigen Diet.Biomedicines · 2025Article
- Associations of Immune Cell Subsets With Coronary Artery Calcium Incidence and Progression in the Multi-Ethnic Study of Atherosclerosis.Journal of the American Heart Association · 2025Observational
- Anti-inflammatory phenotypes of immune cells after myocardial infarction and prospects of therapeutic strategy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Tertiary Lymphoid Structures Across Organs: Context, Composition, and Clinical Levers.Immunological reviews · 2025Review
122 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The cardiovascular system is subject to hyperlipidaemic, inflammatory, and pro-oxidant stressors. Over time, these factors drive prevalent chronic diseases, of which atherosclerosis is most prominent and accounts for the majority of deaths globally. Antibody-producing B cells perform a unique role in responses to stress, injury, and infection. The power, inducibility, and adaptability of the antibody repertoire require an equally complex range of control measures. Defects and chronic perturbations in these checkpoints lead to inappropriate antibody responses, which might have important roles in shaping the development and outcome of atherosclerotic disease. A unique aspect related to atherosclerosis is the prominent role of natural antibodies, specifically those binding to the oxidized epitopes that are abundant on modified lipoproteins and cellular debris. B cells control cellular immune responses through cell-cell contact, antigen presentation, and cytokine production, and thereby participate in systemic and local immune responses in atherosclerotic arteries. To date, both proatherogenic and antiatherogenic properties have been assigned to B cells, depending on subsets and how they are functionally targeted. For these reasons, a deeper understanding of how B cells influence atherosclerotic plaque development is being pursued with the hope of providing novel B cell-targeted interventions to prevent inflammation-driven cardiovascular events.
Indexed as
Identifiers
30410107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.